Q-omics provides the consensus-scored PKD2L2 profile across patient tissues and cancer cell-line models. PKD2L2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PKD2L2 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, PKD2L2 RNA expression shows 18,538 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where PKD2L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PKD2L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PKD2L2 survival associations across molecular data types. PKD2L2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PKD2L2 RNA expression–survival associations across cancer types. High PKD2L2 expression shows unfavorable associations in KIRC, UVM and SCLC, but favorable associations in HNSC, UCS and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PKD2L2 RNA expression.
This table summarizes PKD2L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PKD2L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PKD2L2 shows lower tumor expression in KIRC, KIRP, KICH and BRCA and higher tumor expression in CHOL and LIHC. The KIRC box plot shows higher PKD2L2 RNA expression in normal versus tumor tissue (log2 FC = −0.172, t-test p < 0.001).
This table shows molecular features associated with PKD2L2 in patient tissues and cancer cell lines. In patient samples, PKD2L2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PKD2L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
